Limits...
Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo.

Buerkle MA, Pahernik SA, Sutter A, Jonczyk A, Messmer K, Dellian M - Br. J. Cancer (2002)

Bottom Line: Functional vessel density was markedly reduced on day 3 in treated animals compared to controls (37.2 +/- 12.1 vs 105.2 +/- 11.2 cm(-1); mean +/- s.e.m.; P<0.05) and increased subsequently in both groups.Inhibition of alpha(v)-integrins by a cyclic RGD-peptide resulted in significant reduction of functional vessel density, retardation of tumour growth and metastasis in vivo.Taken together, these results implicate RGD-peptides as agents which have anti-tumour and anti-metastatic activity in vivo.

View Article: PubMed Central - PubMed

Affiliation: Institute for Surgical Research, Klinikum Grosshadern, Marchioninistrasse 15, Ludwig-Maximilians-University, 81377 Munich, Germany.

Show MeSH

Related in: MedlinePlus

Red blood cell velocity (mean±s.e.m.) of control group and RGD treated group. *P<0.05 vs corresponding controls; #P<0.05 vs treatment day 9 and day 13.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2375318&req=5

fig3: Red blood cell velocity (mean±s.e.m.) of control group and RGD treated group. *P<0.05 vs corresponding controls; #P<0.05 vs treatment day 9 and day 13.

Mentions: Similar to vessel density, RBC velocity (vRBC) in tumour vessels of treated animals was markedly below values of controls on day 3 (0.026±0.01 vs 0.12±0.03 mm s−1; P<0.05; Figure 3Figure 3


Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo.

Buerkle MA, Pahernik SA, Sutter A, Jonczyk A, Messmer K, Dellian M - Br. J. Cancer (2002)

Red blood cell velocity (mean±s.e.m.) of control group and RGD treated group. *P<0.05 vs corresponding controls; #P<0.05 vs treatment day 9 and day 13.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2375318&req=5

fig3: Red blood cell velocity (mean±s.e.m.) of control group and RGD treated group. *P<0.05 vs corresponding controls; #P<0.05 vs treatment day 9 and day 13.
Mentions: Similar to vessel density, RBC velocity (vRBC) in tumour vessels of treated animals was markedly below values of controls on day 3 (0.026±0.01 vs 0.12±0.03 mm s−1; P<0.05; Figure 3Figure 3

Bottom Line: Functional vessel density was markedly reduced on day 3 in treated animals compared to controls (37.2 +/- 12.1 vs 105.2 +/- 11.2 cm(-1); mean +/- s.e.m.; P<0.05) and increased subsequently in both groups.Inhibition of alpha(v)-integrins by a cyclic RGD-peptide resulted in significant reduction of functional vessel density, retardation of tumour growth and metastasis in vivo.Taken together, these results implicate RGD-peptides as agents which have anti-tumour and anti-metastatic activity in vivo.

View Article: PubMed Central - PubMed

Affiliation: Institute for Surgical Research, Klinikum Grosshadern, Marchioninistrasse 15, Ludwig-Maximilians-University, 81377 Munich, Germany.

Show MeSH
Related in: MedlinePlus